These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25073801)

  • 1. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
    Cho HY; Kyung MS
    Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
    Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
    Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
    Saygili U; Uslu T; Erten O; Doğan E
    Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors.
    Lertkhachonsuk AA; Buranawongtrakoon S; Lekskul N; Rermluk N; Wee-Stekly WW; Charakorn C
    J Obstet Gynaecol Res; 2020 Nov; 46(11):2287-2291. PubMed ID: 32830422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
    Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
    Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
    Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
    Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.
    Zhang W; Jia S; Xiang Y; Yang J; Jia C; Leng J
    J Int Med Res; 2019 Jan; 47(1):96-104. PubMed ID: 30198356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.
    Cho HY; Kim K; Jeon YT; Kim YB; No JH
    Med Sci Monit; 2013 Mar; 19():230-5. PubMed ID: 23539074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of CA19-9 in ovarian mature cystic teratoma.
    Fan JT; Yan HQ; Malla S; Fan YJ; Xu H; Li DH; Liu Y
    Clin Exp Obstet Gynecol; 2016; 43(4):522-525. PubMed ID: 29734540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
    Zhang W; Wang L; Xin Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
    Chen JM; Gao HY; Wang Q; Li Q
    Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
    Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
    Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.